Published on: December 7, 2020 |
By: Todd Mitchell
Keep an eye on Altimmune Inc. (ALT). The stock is pushing higher thanks to more positive data on its COVID candidate. The company just published positive pre-clinical data for its new single-dose, intranasal COVID-19 vaccine candidate AdCOVID, adding the candidate “stimulates three key immune components: serum neutralizing antibody, T cell responses, and mucosal immunity....
Continue Reading